Table 2 Point prevalencea of the COVID-19 at-risk population in the UK on 5 March 2019, N = 2,706,053
| Â | Â | Scotland | Northern Ireland | Wales | England | ||||
|---|---|---|---|---|---|---|---|---|---|
N = 801,352 | N = 205,092 | N = 708,670 | N = 990,939 | ||||||
| Â | Â | n | Point prevalence /100,000 (95% CI) | n | Point prevalence /100,000 (95% CI) | n | Point prevalence /100,000 (95% CI) | n | Point prevalence /100,000 (95% CI) |
Demographics | Mean age (SD) | Â | 42.3 (22.6) | Â | 40.7 (22.7) | Â | 42.6 (23.2) | Â | 40.8 (22.8) |
Female | 403,151 | 50,309 (50,199–50,418) | 102,545 | 50,000 (49,783–50,216) | 356,080 | 50,246 (50,130–50,363) | 496,988 | 50,153 (50,055–50,252) | |
Ethnicity | |||||||||
 White | 427,954 | 53,404 (53,295–53,513) | 55,293 | 26,960 (26,768–27,153) | 226,425 | 31,951 (31,842–32,059) | 570,706 | 57,592 (57,495–57,690) | |
 South Asian | 9325 | 1164 (1140–1187) | 764 | 373 (347–400) | 7440 | 1050 (1026–1074) | 48,334 | 4878 (4835–4920) | |
 Black | 3989 | 498 (482–513) | 335 | 163 (146–182) | 2861 | 404 (389–419) | 27,947 | 2820 (2788–2853) | |
 Other | 9360 | 1168 (1145–1192) | 1102 | 537 (506–570) | 4497 | 635 (616–653) | 20,106 | 2029 (2001–2057) | |
 Mixed | 2323 | 290 (278–302) | 253 | 123 (109–140) | 2219 | 313 (300–326) | 12,376 | 1249 (1227–1271) | |
 Not recorded | 348,401 | 43,477 (43,368–43,585) | 147,345 | 71,843 (71,648–72,038) | 465,228 | 65,648 (65,537–65,759) | 311,470 | 31,432 (31,340–31,523) | |
Underlying health conditions contributing to the at-risk population | Chronic liver disease | 4125 | 515 (499–531) | 681 | 332 (308–358) | 2150 | 303 (291–316) | 2525 | 255 (245–265) |
Chronic heart disease | 39,804 | 4967 (4920–5015) | 9740 | 4749 (4657–4842) | 34,459 | 4862 (4813–4913) | 37,040 | 3738 (3701–3775) | |
Chronic respiratory disease (other than asthma) | 28,529 | 3560 (3520–3601) | 7846 | 3826 (3743–3910) | 24,192 | 3414 (3372–3456) | 26,821 | 2707 (2675–2739) | |
Current asthma (only) | 47,164 | 5886 (5834–5937) | 14,636 | 7136 (7025–7249) | 51,783 | 7307 (7247–7368) | 61,762 | 6233 (6185–6280) | |
Chronic neurological disease | 29,631 | 3698 (3656–3739) | 6729 | 3281 (3204–3359) | 23,850 | 3365 (3324–3408) | 27,488 | 2774 (2742–2806) | |
Diabetes mellitus | 54,987 | 6862 (6807–6917) | 15,878 | 7742 (7627–7858) | 59,995 | 8466 (8401–8531) | 61,925 | 6249 (6202–6297) | |
Organ transplant recipient | 748 | 93 (87–100) | 182 | 89 (76–103) | 653 | 92 (85–99) | 894 | 90 (84–96) | |
Asplenia/sickle cell disease | 1062 | 133 (125–141) | 244 | 119 (105–135) | 905 | 128 (120–136) | 1337 | 135 (128–142) | |
Other immunosuppression | 7199 | 898 (878–919) | 1616 | 788 (750–827) | 4181 | 590 (572–608) | 6419 | 648 (632–664) | |
Chronic kidney disease | 54,845 | 6844 (6789–6900) | 17,296 | 8433 (8313–8554) | 53,280 | 7518 (7457–7580) | 69,894 | 7053 (7003–7104) | |
Severe obesity (BMI ≥40 kg/m2) | 21,249 | 3315 (3271–3359) | 5256 | 3299 (3211–3387) | 21,431 | 3803 (3753–3853) | 21,282 | 2762 (2725–2799) | |
At-risk population based on underlying health conditions | At-risk population overallb | 196,378 | 24,506 (24,412–24,600) | 53,945 | 26,303 (26,112–26,494) | 187,695 | 26,486 (26,383–26,588) | 223,587 | 22,563 (22,481–22,646) |
 among those aged < 70 years | 126,695 /696,563 | 18,189 (18,098–18,279) | 36,178 /180,643 | 20,027 (19,843–20,213) | 117,628 /603,155 | 19,502 (19,402–19,602) | 143,305 /866,280 | 16,543 (16,464–16,621) | |
 among those aged ≥70 years | 69,683 /104,789 | 66,498 (66,212–66,784) | 17,767 /24,449 | 72,670 (72,106–73,228) | 70,067 /105,515 | 66,405 (66,119–66,690) | 80,282 /124,659 | 64,401 (64,135–64,667) | |
 of school age (5–18 years) | 9680 /127,199 | 7610 (7465–7757) | 3737 /35,846 | 10,425 (10,111–10,746) | 10,105 /115,258 | 8767 (8605–8932) | 13,915 /175,447 | 7931 (7805–8059) | |
 of working age (19–65 years) | 99,786 /508,725 | 19,615 (19,506–19,724) | 27,944 /129,274 | 21,616 (21,392–21,842) | 91,644 /433,284 | 21,151 (21,030–21,273) | 111,409 /618,404 | 18,016 (17,920–18,112) | |
 among males | 93,319 /398,201 | 23,435 (23,304–23,567) | 25,691 /102,534 | 25,056 (24,791–25,323) | 89,178 /352,556 | 25,295 (25,151–25,439) | 106,989 /493,908 | 21,662 (21,547–21,777) | |
 among females | 103,059 /403,151 | 25,563 (25,429–25,698) | 28,251 /102,545 | 27,550 (27,277–27,824) | 98,513 /356,080 | 27,666 (27,519–27,813) | 116,594 /496,988 | 23,460 (23,342–23,578) | |
Multimorbidity | 58,076 | 7247 (7191–7304) | 16,248 | 7922 (7806–8040) | 55,556 | 7839 (7777–7902) | 60,994 | 6155 (6108–6203) | |
Cancer survivors | Incident cancer in previous year | 3439 | 429 (415–444) | 899 | 438 (410–468) | 3164 | 446 (431–462) | 3742 | 376 (364–388) |
Incident cancer in previous 5 years | 12,847 | 1603 (1576–1631) | 3344 | 1630 (1576–1686) | 12,451 | 1757 (1726–1788) | 14,663 | 1480 (1456–1504) | |